uniQure (NASDAQ:QURE) Given New $95.00 Price Target at Guggenheim

uniQure (NASDAQ:QURE) had its target price hoisted by Guggenheim from $28.00 to $95.00 in a research note issued to investors on Thursday morning, Marketbeat reports. Guggenheim currently has a buy rating on the biotechnology company’s stock.

A number of other research firms have also recently issued reports on QURE. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and set a $30.00 price objective for the company in a research report on Thursday, August 14th. Chardan Capital upped their price objective on shares of uniQure from $35.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday. Leerink Partners upped their price objective on shares of uniQure from $48.00 to $68.00 and gave the stock an “outperform” rating in a research report on Wednesday. Royal Bank Of Canada reiterated an “outperform” rating on shares of uniQure in a research report on Wednesday. Finally, Wall Street Zen upgraded shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $64.64.

uniQure Price Performance

QURE stock opened at $52.65 on Thursday. The company has a quick ratio of 9.98, a current ratio of 9.98 and a debt-to-equity ratio of 1.53. uniQure has a 12 month low of $4.45 and a 12 month high of $54.98. The firm has a market cap of $2.89 billion, a P/E ratio of -13.43 and a beta of 0.14. The company’s 50-day moving average price is $16.65 and its two-hundred day moving average price is $14.61.

uniQure (NASDAQ:QURE) last released its earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.20. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. The firm had revenue of $5.26 million for the quarter, compared to analyst estimates of $5.00 million. On average, analysts anticipate that uniQure will post -3.75 earnings per share for the current fiscal year.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC acquired a new position in uniQure in the 1st quarter valued at approximately $2,562,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of uniQure during the first quarter worth $152,000. Assenagon Asset Management S.A. increased its position in shares of uniQure by 355.2% during the first quarter. Assenagon Asset Management S.A. now owns 334,894 shares of the biotechnology company’s stock worth $3,550,000 after buying an additional 261,323 shares during the period. Russell Investments Group Ltd. acquired a new stake in shares of uniQure during the first quarter worth $3,218,000. Finally, XTX Topco Ltd increased its position in shares of uniQure by 127.3% during the first quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company’s stock worth $392,000 after buying an additional 20,720 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.